Sarepta Therapeutics Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Sarepta Therapeutics Bundle
Actionable Strategy Starts Here
Sarepta’s BCG Matrix snapshot shows which therapies are sprinting ahead and which need a rethink — a quick, honest look at Stars, Cash Cows, Dogs, and Question Marks in a high-stakes biotech market. This preview teases the patterns; the full BCG Matrix gives quadrant-by-quadrant evidence, strategic recommendations, and ready-to-use Word and Excel files. Purchase the complete report to cut through the noise and make confident, capital-allocation decisions now.
Stars
ELEVIDYS (DMD gene therapy)
ELEVIDYS, the first FDA‑approved gene therapy for Duchenne muscular dystrophy (approval 2021), is Sarepta’s lead asset in a gene therapy market growing at double‑digit annual rates; DMD affects roughly 1 in 3,500–5,000 male births, creating a focused patient pool. The program drives prescriber interest and payer dialogue but requires continued investment in manufacturing scale, label expansion, and real‑world evidence generation. Hold the share: with scaled production and broader indications, ELEVIDYS can pivot into a substantial cash engine.
DMD leadership position
Commanding presence across DMD centers and KOL networks gives Sarepta a de facto leadership in a market with an estimated 9,000–12,000 diagnosed US patients (2024) and ~7–9% CAGR growth; brand gravity accelerates trial recruitment, guides guideline influence, and shortens adoption cycles. Defending the moat requires sustained medical education, field strength, and lifecycle programs to compound growth.
AAV manufacturing & platform know‑how
Hard-won AAV process, QC and supply know-how positions Sarepta as a category leader in 2024, differentiating its franchise as demand for gene therapies surges. Ongoing capacity build-out is cash-intensive today but directly underpins clinical and commercial velocity. Rising utilization will markedly improve unit economics and margins. The AAV platform is a strategic asset that anchors long-term growth.
Payer access momentum in rare disease
High-cost, one-time rare-disease therapies require heavy payer-access work but create a flywheel: each positive coverage decision reduces friction for subsequent approvals; Zolgensma launched at $2.125M illustrates the million-dollar pricing backdrop. Outcomes-data generation remains resource-intensive, driving near-term spend for long-term leverage.
- Access intensity: high
- Pricing context: $2.125M benchmark
- Strategy: near-term spend, long-term coverage gains
Clinical data flywheel (DMD)
Expanding datasets, patient registries and real-world evidence in DMD (prevalence ~1 in 3,500–5,000 male births) reinforce Sarepta’s leadership by accelerating label expansions and payer confidence. Robust data drives prescriber comfort and supports premium pricing (exon-skipping products ~300,000 USD/year; single-dose gene therapies exceed 2 million USD), but curation is costly. The compounding, proprietary data moat is hard to replicate.
- Datasets → label & payer leverage
- RWE → prescriber adoption
- High maintenance costs
- Durable competitive moat
Gene therapy leader: 9,000–12,000 US DMD market, single‑dose pricing ~$2.125M
ELEVIDYS (FDA 2021) anchors Sarepta’s Star: leadership in a 9,000–12,000 US DMD patient market (2024) with double‑digit gene‑therapy growth; high upfront R&D and manufacturing spend compress near‑term margins but scale drives margin expansion and pricing power (single‑dose benchmarks >$2M).
| Metric | 2024 value |
|---|---|
| Diagnosed US DMD | 9,000–12,000 |
| ELEVIDYS approval | 2021 |
| Gene therapy price benchmark | $2.125M |
What is included in the product
Detailed Word Document
In-depth BCG Matrix of Sarepta’s portfolio: identifies Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page BCG view placing Sarepta Therapeutics units in quadrants to ease strategic decisions
Cash Cows
Exondys 51 (eteplirsen)
Exondys 51 (eteplirsen), approved in 2016 as the first exon‑51 skipping therapy for DMD, retains entrenched use in the ~13% of DMD patients amenable to exon 51 skipping. Mature demand and a stable prescriber base keep incremental promo needs low; with an approximate list price near $300,000/year, it delivers solid margins and reliable cash to fund next‑wave programs.
Vyondys 53 (golodirsen)
Vyondys 53 (golodirsen), approved in 2019, serves the roughly 8% of Duchenne patients amenable to exon 53 skipping. By 2024 it showed predictable volumes and reimbursement patterns across major markets. Growth is limited, but manufacturing and distribution remain efficient and low-cost to support. It continues as a steady contributor to Sarepta’s operating cash flow.
Amondys 45 (casimersen)
Amondys 45 (casimersen) was FDA‑approved on February 25, 2021 for DMD amenable to exon 45 skipping, a mutation present in roughly 8% of DMD patients. As a later RNA‑entry therapy it targets a consistent patient pool; growth is modest but profitability benefits from shared commercial infrastructure and field synergies. Its smaller but steady revenues help underwrite Sarepta’s high‑risk R&D pipeline.
U.S. DMD commercial infrastructure
U.S. DMD commercial infrastructure underpins Sarepta as a cash cow: seasoned market access, robust patient services and a national distribution network now optimized for scale with lower incremental costs, keeping churn low and adherence high; serves an estimated 15,000–20,000 US DMD patients (2024) and quietly throws off dependable cash.
- Market access: national payer relationships
- Patient services: care coordination, adherence support
- Distribution: centralized logistics, lower incremental cost
- Scale impact: steady recurring revenue, low churn
Lifecycle & label maintenance revenues
Lifecycle and label-maintenance revenues from Sarepta's approved exon-skipping and gene-targeted therapies deliver steady, incremental indications and age-range expansions that lift persistence with minimal new launch spend, creating a high-margin tail as DMD markets mature and providing ballast in volatile biotech cycles.
- Incremental indications: label expansions
- Age-range use: broader pediatric/adolescent uptake
- Persistence lift: longer treatment duration
- Low incremental spend vs early launches
- High-margin tail, stabilizes revenue volatility
Exon-targeted DMD therapies cover ~29% of patients; US pool 15,000–20,000; price ~300,000/yr
Exondys 51 (2016), Vyondys 53 (2019) and Amondys 45 (2021) serve ~13%, ~8% and ~8% of DMD patients respectively, with Exondys list price ~300,000/year. US DMD pool est. 15,000–20,000 (2024), mature access and patient services keep promo costs low and margins high, providing dependable cash to fund R&D.
| Therapy | Approval | Patient % | List price (yr) |
|---|---|---|---|
| Exondys 51 | 2016 | ~13% | ~300,000 |
| Vyondys 53 | 2019 | ~8% | — |
| Amondys 45 | 2021 | ~8% | — |
Preview = Final Product
Sarepta Therapeutics BCG Matrix
The file you’re previewing is the final Sarepta Therapeutics BCG Matrix you’ll receive after purchase. No watermarks or demo text—just a fully formatted, analysis-ready report tailored to Sarepta’s portfolio. It’s crafted for strategic clarity and immediate use in presentations or planning. Buy once, download instantly, edit or print as needed.
Dogs
Niche exon programs with ultra-tiny cohorts
Niche exon programs are scientifically compelling but commercially thin for Sarepta: the company has three FDA-approved exon-skipping therapies (Exondys 51, Vyondys 53, Amondys 45) targeting subsets of Duchenne muscular dystrophy, a disease affecting roughly 1 in 3,500–5,000 male births. These ultra-tiny cohorts strain manufacturing and commercial support, tying up R&D and COGS with limited revenue upside. Divest or deprioritize where possible to reallocate capital to broader-impact assets.
Legacy PMO chemistries with limited differentiation
Legacy PMO chemistries at Sarepta are older tech lines that no longer move clinical needles as of 2024, competing poorly against the accelerating gene therapy momentum. They continue to consume CMC bandwidth and cross-functional teams, delaying higher-value programs. Sunseting these assets would free capacity and reduce spend, allowing reallocation toward gene-editing and AAV efforts gaining priority in 2024.
Non-core exploratory collaborations
Non-core exploratory collaborations consist of small, scattered projects outside Sarepta’s neuromuscular core, creating strategic distraction with dilutive ROI that diverts resources from high-potential DMD programs. Governance overhead for these partnerships often outweighs upside, adding contractual and management burdens. Prune low-value collaborations and refocus capital and talent on core gene therapy and oligonucleotide pipelines.
Geographies with persistent access barriers
Geographies with persistent access barriers: long regulatory engagement through 2024 still yields closed reimbursement channels in key markets, high pricing friction and limited uptake for Sarepta therapies.
These dynamics create cash-trap risks as launch investments fail to convert to sales; pause commercialization expansion until HTA and payer conditions change.
- Access: prolonged regulatory delays
- Payers: high pricing friction, low uptake
- Financial: cash-trap dynamics
- Action: pause expansion until policy shifts
Obsolete assay and support tools
Dogs: Obsolete assay and support tools — legacy diagnostics and field tools >10 years old add cost, not value; upkeep diverts lab bandwidth from core programs while Sarepta's 2024 revenue >$1B demands lean allocation. Maintenance burdens the team and increases time-to-data; modernize or retire to cut drag on pipeline throughput and operating efficiency.
Retire legacy diagnostics — save $20–30M, free labs for gene therapy
Legacy diagnostics and field tools (>10 years old) are low-growth, low-share Dogs draining lab time and ~$20–30M annual maintenance versus Sarepta’s 2024 revenue >$1B. Retire or modernize to save OPEX, reduce time-to-data and reallocate staff to gene therapy programs.
| Metric | Value |
|---|---|
| Maintenance spend | $20–30M |
| Revenue 2024 | >$1B |
Question Marks
Ex-U.S. ELEVIDYS expansion
Ex-U.S. ELEVIDYS expansion is a Question Mark: large unmet DMD potential after FDA accelerated approval on September 21, 2023, but low current share pending regulatory and HTA wins across Europe and Japan. High cash needs for filings, pharmacovigilance, and access campaigns will strain Sarepta’s balance sheet given cash and equivalents were $1.04 billion at Dec 31, 2023. If major reimbursements land, ELEVIDYS could flip to a Star quickly; absent them it risks drifting toward Dog.
Limb‑Girdle MD gene therapies
Limb‑girdle MD gene therapies target an attractive, high‑unmet‑need space—as of 2024 LGMD comprises over 30 genetic subtypes—yet commercial uptake is early. Manufacturing and dosing are heavy: many AAV programs use doses exceeding 1e14 vector genomes/kg, driving COGS and supply constraints. Clinical milestones (pivotal efficacy/safety, approvals) will determine value. Invest via milestone‑linked tranches and partner for manufacturing and commercialization capacity.
Gene editing (e.g., CRISPR-based) programs
Gene editing programs at Sarepta are question marks: they sit in a high-growth, high-interest category but currently account for a small portion of the pipeline and revenues. Technical risk, intensified FDA and EMA scrutiny, and complex CMC make development and approval uncertain. Programs are cash-intensive with long timelines; success requires winning proof-of-concept signals and then scaling rapidly to capture market share.
Next‑gen AAV capsids and delivery
Next‑gen AAV capsids and delivery for Sarepta are promising for broader tissue reach and dosing efficiency; 2023–24 preclinical data reported up to 100‑fold dose reductions and expanded transduction beyond muscle into CNS/heart in animal models. It remains platform R&D with no market share, needing sustained capital, external validation, and could unlock multiple Stars if clinical translation succeeds.
- Platform: next‑gen AAV capsids
- Status: preclinical/early clinical, no market share
- Impact: up to 100x dose efficiency (2023–24 data)
- Risk: capital intensity, validation required
- Upside: could convert into multiple Stars
New neuromuscular indications beyond DMD
New neuromuscular indications beyond DMD show clear clinical demand—DMD prevalence ~1:3,500–5,000 male births—but Sarepta’s commercial footprint outside DMD remains nascent; market education and payer groundwork are substantial given gene therapy price precedents (Zolgensma ~$2.125M). Portfolio fit is strong, timelines are long; stage-gate aggressively to prevent drift.
Post-approval gene therapy: weak ex-US uptake, $1.04B cash limits, supply risk
Ex‑U.S. ELEVIDYS is a Question Mark: accelerated FDA approval Sep 21, 2023 but low ex‑US share; Sarepta cash $1.04B (Dec 31, 2023) may constrain filings. LGMD gene therapies target 30+ subtypes (2024) with uncertain uptake; high‑dose AAV COGS and supply risk. Gene editing and next‑gen capsids are preclinical, capital‑intensive and regulatory‑uncertain.
| Asset | Status | Key metric |
|---|---|---|
| ELEVIDYS ex‑US | Launch/Access | Cash $1.04B (12/31/23) |
| LGMD | Early | 30+ subtypes (2024) |